EGFR and non-small cell lung carcinoma: Indeed, the resistance of non-small cell lung cancer (NSCLC) to several RTK inhibitors, including those targeting EGFR-, ALK-, and MET-signaling, has been shown to result from EMT [21,22,23,24,25].